This website is for Australian audiences only

Examine the burden of disease of PsA

The prevalence of comorbidities in patients with PsA

PsA is frequently associated with comorbidities that could affect the disease outcome and can impact a patient’s daily functioning and quality of life.1,2 To optimize important patient outcomes, physicians should globally assess disease activity and consider the impact of comorbidities on management decisions.1

~70% of patients experience at least one comorbidity1,3
Up to 40% of patients have more than three comorbidities3

Common comorbidities in patients with PsA include:

Depression4 Cardiovascular disease4 Diabetes5 Fibromyalgia6 Osteoporosis4 Obesity7 Metabolic syndrome8 Depression4 Cardiovascular disease4 Diabetes5 Osteoporosis4 Fibromyalgia6 Obesity7 Metabolic syndrome8

LECTURE SERIES WITH DR. SAAKSHI KHATTRI

The art of assessing the multiple disease domains of PsA and common comorbidities

Join Dr. Khattri as she discusses the complexity of managing patients with PsA who are experiencing comorbidities and multiple-domain involvement, and why a multidisciplinary approach is needed.

Recognizing the total burden of disease of PsA

PsA has a negative impact on patients’ quality of life, across all disease domains. For example:

  • Patients with enthesitis and dactylitis report increased disability from reduced physical functioning, as well as increased sleep disturbances and fatigue4,9,10
  • Patients report itching at the location of skin involvement in psoriasis, and pain/swelling of joints as factors contributing the most to disease severity11
  • Nail disease and disfiguration have been associated with physical and emotional distress and decreased productivity at work4

The quality of life for patients with PsA is further reduced by experiencing clinical presentations across multiple disease domains, comorbidities, and increased disease severity.12

It is important to consider all aspects of disease activity when managing patients with PsA—from specific measures of the various disease domains to assessing the impact on a patient’s quality of life.1,2

Explore the disease outcome measures used for PsA in our exhibit

How can underlying causes of disease affect the burden to patients?

A deeper understanding of the pathological processes that cause certain disease manifestations may help reduce the impact on patients’ burden of disease.

Gaze upon the Gallery of Cytokines

NEXT EXHIBIT IN THE PSA TOUR

PsA outcomes

Explore different disease outcome measures and their importance in defining PsA disease activity in clinical practice.

Continue PsA tour Back to: Clinical manifestations

PREVIOUS ROOM

Clinical manifestations

Back to previous

  1. Lubrano E, Scriffignano S, Belen Azuaga, A, et al. Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study. Rheumatol Ther. 2020;7:825-836. doi.org/10.1007/s40744-020-00229-0
  2. Gupta S, Syrimi Z, Hughes DM, et al. Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int. 2021;41:275–284. doi.org/10.1007/s00296-020-047
  3. Husted JA, Thavaneswaran A, Chandran V, et al. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol. 2013;40(8):1349-1356. doi:10.3899/jrheum.121500
  4. Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T. 2010;35(12):680-689.
  5. Dal Bello G, Gisondi P, Idolazzi L, et al. Psoriatic arthritis and diabetes mellitus: a narrative review. Rheumatol Ther. 2020;7(2):271-285. doi:10.1007/s40744-020-00206-7
  6. Magrey MN, Antonelli M, James N, et al. High frequency of fibromyalgia in patients with psoriatic arthritis: a pilot study. Arthritis. 2013;2013:762921. doi:10.1155/2013/762921
  7. Tam LS, Tomlinson B, Chu TT, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls--the role of inflammation. Rheumatology (Oxford). 2008;47(5):718-723. doi:10.1093/rheumatology/ken090
  8. Raychaudhuri SK, Chatterjee S, Nguyen C, et al. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8(4):331-334. doi:10.1089/met.2009.0124
  9. Kaeley GS, Eder L, Aydin SZ, Gutierrez M, et al. Enthesitis: A hallmark of psoriatic arthritis. Semin Arthritis Rheum. 2018;48(1):35-43. doi:10.1016/j.semarthrit.2017.12.008
  10. Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3(1):91-102. doi:10.1007/s40744-016-0029-z
  11. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871-881.e830. doi:10.1016/j.jaad.2013.12.018
  12. Ogdie A, Hur P, Liu M, et al. Effect of multidomain disease presentations on patients with psoriatic arthritis in the corrona psoriatic arthritis/spondyloarthritis registry. J Rheumatol. 2021;48(5):698-706. doi:10.3899/jrheum.200371

The information provided is intended to inform and does not replace the advice of your healthcare professional. For any questions regarding inflammatory arthritis and its treatment, please talk to your healthcare professional.

This website is not intended for reporting of adverse events or product complaints regarding UCB products. If you think you may be experiencing a side effect after using a medicine, seek advice from a healthcare professional as soon as possible.

If you wish to report an adverse event or product complaint regarding a UCB product, you can contact UCB Australia via ucbcares.au@ucb.com or phone 03 9828 1800 (Option 3). Alternatively, you may report information on adverse events directly to the TGA at https://www.tga.gov.au/safety/reporting-problems.

© 2025 UCB Australia Pty Ltd. (ABN 48 005 799 208). Level 1, 1155 Malvern Rd. Malvern VIC 3144, Australia.
Telephone: +61 (3) 9828 1800. Facsimile: +61 (3) 9828 1860. February 2025. AU-DA-2400173

Exiting RheuMuseum?

The information you are about to be referred to may not comply with the Australian regulatory environment. Please refer to the Product Information or Consumer Medicines Information for products to fully understand the terms of a product’s registration in Australia.

The intent of providing this material is informational and not as advice.

Any information provided by this source should be discussed with your healthcare professional and does not replace their advice.

OK